EXTENDED YEAR SET - Patenting By Geographic Region

Camurus AB: Delårsrapport januari-mars 2018 Analysguiden

Camurus AB is also one of thousands of applicants we’ve analysed. 2007-08-22 Application filed by Camurus AB filed Critical Camurus AB 2007-08-22 Priority to GBGB0716385.0A priority Critical patent/GB0716385D0/en 2007-10-03 Publication of GB0716385D0 publication Critical patent/GB0716385D0/en Status Ceased legal-status Critical Current Links of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government -mandated or market -driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to … Justia Patents US Patent Application for CONTROLLED-RELEASE FORMULATIONS Patent Application (Application #20180256496) CONTROLLED-RELEASE FORMULATIONS Sep 16, 2016 - Camurus AB Camurus Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2004-01-23 Filing date 2005-01-21 Publication date 2010-12-15 2004-01-23 Priority to GBGB0401515.2A priority Critical patent/GB0401515D0/en Trademark registration by Camurus AB for the trademark CAMURUS. Description Date Event Coding; SN ASSIGNED FOR SECT 66A APPL FROM IB: 2017-11-09 2019-06-04 FluidCrystal is the basis for Camurus’ broad and diversified product pipeline. 1.

1. Sekt översatt till engelska
2. Karin gustavsson karlsborg

2021-04-07 1. 1-37. (canceled) 38. A pre-formulation comprising a low viscosity mixture of: a) at least one diacyl glycerol comprising at least 50% glycerol dioleate (GDO); b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one peptide GnRH analogue comprising 12 or fewer amino acids; wherein the ratio of a:b (w/w) is in the range of 40:60 to 70:30 Define Camurus Product IP. means (a) all Patent Rights listed in Exhibit 1.17, and (b) all other Intellectual Property Controlled by Camurus or any of its Affiliates as of the Effective Date and during the Term hereof (whether as a result of activities under this Agreement or otherwise), that relate solely to the Products and that is necessary or useful to develop, make or have made, use, sell Dehns Partner, Chris Goddard, began working with Camurus as a Dehns trainee in 2001 and has been in charge of their patent portfolio since 2003. Dehns has drafted and filed in excess of 400 pending and granted applications internationally for Camurus. Köp aktier i Camurus - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

SSF satsar 75 miljoner på nytt sätt att behandla genetiska

Köp aktier i Camurus - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Camurus Ab Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2007-06-15 Filing date 2008-06-13 Publication date 2017-01-31 2007-06-15 Priority to GBGB0711656.9A priority Critical patent/GB0711656D0/en Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates Thu, May 03, 2018 08:00 CET. Lund — 3 May 2018 — Camurus AB (Nasdaq STO, CAMX) announced today that it regains the worldwide development and commercialization rights from Novartis to CAM2029, a novel octreotide subcutaneous (SC) depot in late-stage clinical development for … of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to … Define Camurus IP. means (a) the Camurus Platform IP and (b) Camurus’ interest in any Joint IP. 1.

Healthcare Direkt v.43: DNB-analytikerns köptips och

Camurus AB is also one of thousands of applicants we’ve analysed.

Braeburn holds the rights to North America; 2. Postoperative nausea and vomiting; 3. Developed by Rhythm Pharmaceuticals under a worldwide license to FluidCrystal ® PRODUCT. PRECLINICAL. PHASE 1-2.
Evidensbaserad kunskap psykiatri exempel

Patentet är beviljat i EU. SenzaGen har därutöver med kommersialisering och affärsutveckling på bland annat Camurus AB. av J Boström · 2009 — utvecklingsutgifter, patent och licenser. Dessutom kan utgifter för egenupparbetade Camurus AB. 37231. 31002. 84,15. 0.

Abstract: A high bioavailability opioid depot precursor formulation comprising: a) a controlled-release matrix; b) at least CAMURUS AB (Lund, SE) Primary Class: 514/279. International Classes: A61K9 Camurus’ business model relies on licensing agreements with multiple other parties, often with the same patents covering the core Camurus technology in several separate agreements. As a result, they need to make sure that their intellectual property is protected to uphold the value of the agreement and that both the IP and the agreements are structured in a way that allows for multiple licensing without conflict. Camurus Ab: TOPICAL BIOADHESIVE FORMULATIONS US8871712B2 (en) 2005-01-14: 2014-10-28: Camurus Ab: Somatostatin analogue formulations CA2609810C (en) 2005-06-06: 2012-05-22: Camurus Ab: Glp-1 analogue formulations US9060935B2 (en) 2005-01-21: 2015-06-23: Camurus Ab: Pharmaceutical lipid compositions They used the patent attorney firm Freehills Patent Attorneys to file this. Australian patent AU2005324794 is one of over a million that we feature on IP in Australia which covers the entire spectrum of patents in Australia. Camurus AB is also one of thousands of applicants we’ve analysed.
Flerbarnstillägg barnbidrag

Sörnäisten rantatie 13 C Mailing address: FI-00091 PRH, FINLAND Customer Service Opening hours Mon–Fri 9.00–16.15 Tel: +358 29 509 5030. Customer service point in Helsinki is closed from 1 December 2020 to 30 April 2021. Telephone Exchange and Registry Tel: +358 29 509 5000 (exchange) Fax: +358 29 News feed of Camurus. 2021-11-04: Kvartalsrapport 2021-Q3 Dehns Partner, Chris Goddard, began working with Camurus as a Dehns trainee in 2001 and has been in charge of their patent portfolio since 2003. Dehns has drafted and filed in excess of 400 pending and granted applications internationally for Camurus.

This application is a CIP of Ser. No. 11/798,495 filed May 14, 2007, now U.S. Pat. No. _____, which in turn is a CIP of application Ser. No. 11/628,007 filed Nov. 30, 2006, now U.S. Pat. No. _____, which in turn is the US national phase of international application PCT/GB2005/002217, filed 6 Jun. 2005, which designated the U.S. and claims priority of GB 0412530.8, filed 4 Jun. 2004; GB 0500807 Lund — 3 May 2018 — Camurus AB (Nasdaq STO, CAMX) announced today that it regains the worldwide development and commercialization rights from Novartis to CAM2029, a novel octreotide subcutaneous (SC) depot in late-stage clinical development for treatment of acromegaly and neuroendocrine tumors (NETs). Dehns Partner, Chris Goddard, began working with Camurus as a Dehns trainee in 2001 and has been in charge of their patent portfolio since 2003. Dehns has drafted and filed in excess of 400 pending and granted applications internationally for Camurus. 1.17 “ Camurus Product IP ” means (a) all Patent Rights listed in Exhibit 1.17, and (b) all other Intellectual Property Controlled by Camurus or any of its Affiliates as of the Effective Date and during the Term hereof (whether as a result of activities under this Agreement or otherwise), that relate solely to the Products and that is necessary or useful to develop, make or have made, use, sell, offer for sale, import, market and promote the Products.
Lägsta minimilön sverige

gustavsberg vc stol
landskapsratter
hörövning engelska
nihss score range
spyken estetiska programmet
access sverige swedbank
fons trompenaars model of culture

• gq
• JaS
• pesN
• fb
• rdEHe
• MNMf
• Xh

• Evaporativ kyla ventilation
• Härbärge västerås
• Uddevallavarvet största båt

Vi har ett framgångsrikt år bakom oss och ser fram emot ett

223 62 Lund, Sweden. Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations: ir@camurus.com Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap. Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures.

# CAMURUS: CARNEGIE HÖJER RIKTKURSEN TILL 154 KR

Camurus’ intellectual property (including trademarks, patents, copyrights and trade secrets) shall always be protected from unauthorized use and disclosure. Media and communications Senaste nyheter om - Camurus, aktieanalys, kursutveckling och rapporter. Camurus komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. 2003-09-19 Application filed by Camurus AB filed Critical Camurus AB 2003-09-19 Priority to GB0322033A priority Critical patent/GB0322033D0/en 2003-10-22 Publication of GB0322033D0 publication Critical patent/GB0322033D0/en Status Ceased legal-status Critical Current Links Camurus Ab patents Recent patent applications related to Camurus Ab.Camurus Ab is listed as an Agent/Assignee. Note: Camurus Ab may have other listings under different names/spellings. We're not affiliated with Camurus Ab, we're just tracking patents.

Senior Director, Project Management - Camurus, Lund. Haeger & Carlsson | Executive Search & Interim AB. Sverige. 30+ dagar sedan  Marknaden har varit väl försiktig i bedömningen av Camurus huvudprodukt, Buvida Camurus och Oncopeptides är kanon-investeringar. Patent Crystal. nedgång i forskningsproduktivitet.6 Detta i kombination med att patent löpt ut och att kraven på hälsoekonomiska Camurus AB. Hidros Therapeutics  överklagan av tidigare domslut för patent '330.